only healthy volunteers are included
Conditions
Interventions
Trade Name: Timoptic 0.5%
Product Name: Timoptic 0.5%
Pharmaceutical Form: Eye drops*
INN or Proposed INN: Timolol
Concentration unit: % percent
Concentration type: equal
Concentration number: 0.5-
T
Sponsors
Department of Clinical Pharmacology, Medical University of Vienna
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 54 healthy male subjects Men aged between 19 and 35 years, nonsmokers - Body mass index between 15th and 85th percentile (Must et al. 1991) - Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant - Normal ophthalmic findings, ametropy =65 years) F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study -Treatment in the previous 3 weeks with any drug -Symptoms of a clinically relevant illness in the 3 weeks before the first study day - Blood donation during the previous 3 weeks - Presence of intraocular pathology: ocular hypertension, glaucoma, retinal vasculopathy or other retinal diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the influence of common topical glaucoma therapy on ONH blood flow regulation during changes in IOP and systemic arterial blood pressure.;Secondary Objective: none;Primary end point(s): as scheduled by protocol | — |
Countries
Austria
Outcome results
None listed